Physician

Chitra Venkatraman, M.D.

According to 2025 Medicare claims, Chitra Venkatraman, M.D. (NPI: 1558354860) practices hematology/oncology in the Washington, DC-MD market, with the plurality of this provider's patient population coming from Prince Georges, MD. This provider's primary affiliated billing organization is CHITRA VENKATRAMAN, M.D., P.A. (NPI: 1962431718; TIN: 522208885) and primary practice location at 20770-2279.

Venkatraman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 690 traditional Medicare patients, billed 144,000 HCPCS/CPT codes, and received $2,571,989 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 596 prescription claims across 171 beneficiaries totaling $3,755,286 in drug costs, led by Verzenio (Abemaciclib). DME data shows 34 claims. Open Payments data shows 26 records totaling $699. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,468,201 to $2,571,989. Similarly, Part D prescription costs have moved sharply higher in recent years, from $844,242 to $3,755,286. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	813	316,459	$1,468,201
2016	917	195,466	$1,466,117
2017	908	206,172	$1,929,748
2018	909	140,406	$1,986,670
2019	974	171,985	$2,899,028
2020	936	285,967	$3,688,042
2021	863	275,931	$3,820,139
2022	811	209,960	$2,707,544
2023	840	157,855	$2,355,199
2024	690	144,000	$2,571,989

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	109	367	$844,242
2016	117	463	$1,081,107
2017	106	322	$815,184
2018	131	455	$1,309,935
2019	124	443	$1,232,155
2020	116	415	$1,598,091
2021	140	490	$2,180,892
2022	133	524	$2,964,939
2023	120	423	$3,242,424
2024	171	596	$3,755,286

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	40	$17,983
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	31	$1,461
2023	N/R	70	$10,016
2024	N/R	34	$526

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	101	151	$159
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	397	828	$113
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	432	1,297	$79
96372	Injection of drug or substance under skin or into muscle	91	386	$13
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	545	1,922	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Verzenio	Abemaciclib	47	1,400	$1,003,567
Lenalidomide	Lenalidomide	42	1,169	$684,206
Revlimid	Lenalidomide	29	721	$467,402
Imbruvica	Ibrutinib	24	694	$405,852
Ibrance	Palbociclib	11	308	$199,515

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$313
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	19	$213

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	26	$699	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Chitra Venkatraman, M.D.?

Tedicare shows public-source Medicare data for Chitra Venkatraman, M.D. (NPI 1558354860), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Chitra Venkatraman, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Chitra Venkatraman, M.D.?

Chitra Venkatraman, M.D. is linked to CHITRA VENKATRAMAN, M.D., P.A. (billing NPI 1962431718) in the available physician profile data.

Does Chitra Venkatraman, M.D. have Open Payments data?

Chitra Venkatraman, M.D. has 26 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.